Aktis Oncology (NASDAQ:AKTS – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Aktis Oncology to related companies based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, earnings and valuation.
Valuation and Earnings
This table compares Aktis Oncology and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Aktis Oncology | $10.06 million | -$63.73 million | -19.71 |
| Aktis Oncology Competitors | $768.41 million | $11.71 million | -18.32 |
Aktis Oncology’s competitors have higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.3% of Aktis Oncology shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Aktis Oncology and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aktis Oncology | 1 | 0 | 9 | 1 | 2.91 |
| Aktis Oncology Competitors | 9923 | 15317 | 45694 | 1603 | 2.54 |
Aktis Oncology presently has a consensus price target of $35.62, suggesting a potential upside of 120.45%. As a group, “Biotechnology” companies have a potential upside of 131.27%. Given Aktis Oncology’s competitors higher possible upside, analysts plainly believe Aktis Oncology has less favorable growth aspects than its competitors.
Profitability
This table compares Aktis Oncology and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aktis Oncology | -727.04% | -26.86% | -18.13% |
| Aktis Oncology Competitors | -12,224.09% | -202.33% | -31.23% |
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
